Abstract:Rosacea is a chronic skin inflammatory disease with a global prevalence ranging from 1% to 20%. It is characterized by facial erythema, telangiectasia, papules, pustules, and ocular manifestations. Its pathogenesis involves a complex interplay of genetic, environmental, immune, microbial, and neurovascular factors. Recent studies have advanced our understanding of its molecular basis, focusing on toll-like receptor (TLR) 2 pathways, LL37 expression, mammalian target of rapamycin (mTOR) activation, interleukin (IL)-17 signaling, transient receptor potential vanilloid (TRPV) functions, and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. LL37-associated signaling pathways, particularly involving TLR2 and mTORC1, are critical in the pathogenesis of rosacea. LL37 interacts with signaling molecules such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), nuclear factor kappa B (NF-κB), inflammasomes, C-X-C motif chemokine ligand 8 (CXCL8), mas-related G-protein-coupled receptor X2 (MRGPRX2)-TRPV4, and vascular endothelial growth factor (VEGF). This interaction activates macrophages, neutrophils, mast cells, and vascular endothelial cells, leading to cytokine release including tumor necrosis factor-alpha (TNF-α), IL-6, IL-1β, C motif chemokine ligand (CCL) 5, CXCL9, and CXCL10. These processes contribute to immune response modulation, inflammation, and angiogenesis in rosacea pathophysiology. The IL-17 signaling pathway also plays a crucial role in rosacea, affecting angiogenesis and the production of inflammatory cytokines. In addition, recent insights into the JAK/STAT pathways have revealed their integral role in inflammatory and angiogenic mechanisms associated with rosacea. Rosacea treatment currently focuses on symptom management, with emerging insights into these molecular pathways providing more targeted and effective therapies. Biological agents targeting specific cytokines, IL-17 inhibitors, JAK inhibitors, and VEGF antagonists are promising for future rosacea therapy, aiming for enhanced efficacy and fewer side effects. This review provides a comprehensive overview of the current knowledge regarding signaling pathways in rosacea and potential targeted therapeutic strategies.

Isosilybin A exhibits anti-inflammatory properties in rosacea by inhibiting MAPK pathway and M1 macrophage polarization

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Artemisinin, a Potential Option to Inhibit Inflammation and Angiogenesis in Rosacea.

Quercetin attenuates inflammation in rosacea by directly targeting p65 and ICAM-1

Rosmarinic Acid Down‐regulates NO and PGE 2 Expression Via MAPK Pathway in Rat Chondrocytes

Aspirin alleviates skin inflammation and angiogenesis in rosacea

Supramolecular salicylic acid ameliorates rosacea-like eruptions by suppressing NLRP3-mediated inflammasome activation in mice

Targeting the STAT3/IL-36G Signaling Pathway Can Be a Promising Approach to Treat Rosacea

Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea

Signaling pathways and targeted therapy for rosacea

Rosmarinic acid nanomedicine for rheumatoid arthritis therapy: Targeted RONS scavenging and macrophage repolarization

Oroxylin A Suppress LL-37 Generated Rosacea-Like Skin Inflammation Through the Modulation of SIRT3-SOD2-NF-κB Signaling Pathway.

Rosmarinic acid inhibits poly(I:C)-induced inflammatory reaction of epidermal keratinocytes

Cell-free adipose tissue extracts as a novel treatment for rosacea by downregulating TRPV1

Rosmarinic Acid Attenuates the Lipopolysaccharide-Provoked Inflammatory Response of Vascular Smooth Muscle Cell via Inhibition of MAPK/NF-κB Cascade

Isopsoralen ameliorates rheumatoid arthritis by targeting MIF

Hydroxychloroquine is a Novel Therapeutic Approach for Rosacea

Astilbin reduces ROS accumulation and VEGF expression through Nrf2 in psoriasis-like skin disease

Mast cell stabilization: new mechanism underlying the therapeutic effect of intense pulsed light on rosacea

Dietary supplementation of n-3 PUFAs ameliorates LL37-induced rosacea-like skin inflammation via inhibition of TLR2/MyD88/NF-κB pathway

Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines